UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 15, 2009
Savient Pharmaceuticals, Inc. |
(Exact Name of Registrant as Specified in Charter)
Delaware | 0-15313 | 13-3033811 |
(State or Other Juris-
diction of Incorporation | (Commission
File Number) | (IRS Employer
Identification No.) |
One Tower Center
East Brunswick, NJ |
08816
|
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: 732-418-9300
|
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On October 15, 2009, Savient Pharmaceuticals, Inc. (the “Company”) announced the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 645,000 shares of common stock. As a result, the Company sold a total of 4,945,000 shares of its common stock at a price to the public of $13.29 per share. After underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds of approximately $60.9 million. The Company’s press release dated October 15, 2009 announcing the closing of the offering is filed as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
| |
99.1 | Press Release of the Company dated October 15, 2009. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | Savient Pharmaceuticals, Inc. |
| Date: October 15, 2009 | | By: | /s/ Philip K. Yachmetz |
| | | | Philip K. Yachmetz
SVP, General Counsel & Secretary |
| | | | |
EXHIBIT INDEX
| |
99.1 | Press Release of the Company dated October 15, 2009. |
